we're working closely with the fda as well as our outside partner quantec. what we've seen when is we get products back on the shelf, customers are really demanding them. i think there's a lot of opportunities for us to be very optimistic about. for example, our pharmaceutical area, over the last five years we've probably had more new innovative brands launched than just about any other major pharmaceutical companies. products like zytega for prostate cancer. another product that's recently launched is zyrelto in our cardiovascular area. we're working on key coronary syndrome. we're expanding on the hiv platform. >> the medical device business more than any other business is closely tied to economics. so when things went down in 2008, you really saw a sharp impact on that business. how's it going? >> it is unique that over the last few years, particularly with the significant macro economic issues and the economic downturn, i think we have some pretty good insights into what's happening with utilization. and for the first time since we've been tracking data,